Navigation Links
Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Date:2/25/2009

limited therapeutic choices."

The picoplatin data will be presented in a poster session on Friday, February 27, at 11:45 a.m. Eastern Time (abstract #186/poster #A38) during the American Society of Clinical Oncology's (ASCO) 2009 Genitourinary Cancers Symposium in Orlando, Fla. Picoplatin, the Company's lead product candidate, is a new generation platinum-based chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations for the treatment of solid tumors.

Phase 2 CRPC Trial Design and Results to Date

Patient enrollment in the ongoing Phase 2 trial of picoplatin in patients with metastatic CRPC was completed in December 2007. The trial enrolled 30 patients with metastatic CRPC who had not received prior chemotherapy. The objective of the study is to evaluate the efficacy and safety of intravenous picoplatin (120 mg/m squared) administered every three weeks in combination with full doses of docetaxel (75 mg/m squared) with daily prednisone (5 mg) as a first-line treatment. PSA response (defined as a PSA reduction of at least 50 percent from baseline maintained for at least four weeks) is the primary endpoint; secondary endpoints include safety, radiologic response, time to progression and overall survival.

The latest trial findings, scheduled for presentation at the ASCO 2009 GU Symposium, demonstrated that:

  • Reductions of PSA levels of at least 50 percent were achieved in 21 of 27 (78 percent) evaluable patients who received picoplatin in combination with docetaxel and prednisone. In contrast, data from published literature report PSA responses of approximately 45 percent in patients who received docetaxel/prednisone.
  • To date, the median time to PSA progression is 8.5 months with picoplatin in combination with docetaxel and prednisone.
  • Radiologic response
    '/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
2. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
4. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
5. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
8. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 METTLER TOLEDO’s newly improved XS ... balances as well as a dual range ... the new SmartPan™ weighing pan delivers results up to ... all balances, ergonomic design details mean users no longer ... for long periods in front of the balance. Barbara ...
(Date:10/1/2014)...  Spherix Incorporated (Nasdaq: SPEX) -- an intellectual property development ... intellectual property, announced today that the Markman hearing ... the U.S. District Court for the Northern District ... rescheduled for November 10, 2014.  This hearing was ... Order setting the Markman date was received after ...
(Date:10/1/2014)... Today the National Institutes of ... for the Brain Research through Advancing Innovative Neurotechnologies ... and revolutionize new methods of understanding the complexities ... This first round of grants totaling $46 million ... to more than 100 investigators in 15 states ...
(Date:10/1/2014)... 2014 Slone Partners , a ... IT, and Laboratory Testing industries, reported a 120% increase ... director level and above from July 2013 to July ... top of rapid breakthroughs in diagnostics, reimbursement has failed ... have been forced to fold, consolidate, or carry on ...
Breaking Biology Technology:METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 3Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2
... Nov. 28 Life scientists are highly,engaged users ... preliminary,results of a worldwide study of more than ... provider of market research services. The,survey, co-sponsored by ... business-to business advertising and marketing,agency, found that 77 ...
... antibody,engineering company developing novel antibodies and antibody fragments,based on ... raised EUR 3.0 million from Novo A/S in a ... by Aescap Venture and Atlas Venture.,After this Second Closing, ... EUR 9.0 million. In total, the Company has raised ...
... testing demonstrate ANAVEX 1-41 has significant ... neuroprotective and anti-amnesic benefits, GENEVA, Nov. ... is pleased to announce promising developments with,ANAVEX 1-41, the ... animal studies, ANAVEX 1-41 prevented oxidative stress,which damages and ...
Cached Biology Technology:Scientists Using Social Media to Inform Lab Purchasing Decisions 2Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 2Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 3Anavex advances drug candidate for treatment of Alzheimer's disease 2Anavex advances drug candidate for treatment of Alzheimer's disease 3Anavex advances drug candidate for treatment of Alzheimer's disease 4Anavex advances drug candidate for treatment of Alzheimer's disease 5
(Date:9/29/2014)... A species of gut bacteria called Clostridium ramosum , ... weight. The work is published this week in mBio ... Microbiology. , A research team from the German Institute ... human gut bacteria including C. ramosum gained weight ... C. ramosum were less obese even when consuming ...
(Date:9/29/2014)... Monday, September 29: Between 1970 and 2010 populations ... the globe dropped 52 percent, says the 2014 ... Fund (WWF). This biodiversity loss occurs disproportionately in ... of high-income countries. , In addition to the ... point to other warning signs about the overall ...
(Date:9/29/2014)... should use ventilation when cooking with a gas stove, ... new study showed an association between gas kitchen stove ... "In homes where a gas stove was used without ... than in homes where a gas stove was used ... the College of Public Health and Human Sciences at ...
Breaking Biology News(10 mins):Gut bacteria promote obesity in mice 2Half of global wildlife lost, says new WWF report 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 3
... from the Asian continent, Drosophila suzukii has only been ... into the Iberian Peninsula, it accelerated towards the north of Europe ... are cherries and red fruits but any type of fruit is ... a threat to the fruit of more and more European countries. ...
... 2012)A rapid increase in shipping in the formerly ice-choked ... risk to the region,s marine mammals and the local ... cultural identity, according to an Alaska Native groups and ... workshop. , The workshopwhich ran from March 12-14examined ...
... Naval Research (ONR) will bring its technologically advanced fuel ... Pacific Operational Science & Technology (S&T) Conference in Honolulu, ... strategic area for the Navy and Marine Corps," said ... worldwide leaders in S&T at this event to discuss ...
Cached Biology News:An invasive Asian fly is taking over European fruit 2Increase in Arctic shipping poses risk to marine mammals 2Increase in Arctic shipping poses risk to marine mammals 3Increase in Arctic shipping poses risk to marine mammals 4ONR outreach focuses on Pacific total force 2
Unit Definition: 1 U corresponds to the amount of enzyme which produces 1 mol protons per minute at pH 5.5 and 30C (peptin from citrus peel, Fluka-No. 76280, as substrate)...
ANTI STENOTROPHOMONAS MALTOPHILIA...
... Features Convenient platform for tube handling ... 96 x 0.2ml V-bottom tubes - ... Plates - Thermo-Fast® 96 Non-Skirted Plate ... - 48 x 0.5ml Thermo-Tubes Multiple workstations ...
... 96 well Magnetic-Ring Stand is designed for ... U-bottom microplates. The stand has a plastic ... microtiter plate footprint. The use of 96 ... and easy magnetic separation. With this magnetic ...
Biology Products: